| Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis E Bråkenhielm, N Veitonmäki, R Cao, S Kihara, Y Matsuzawa, ... Proceedings of the national academy of sciences 101 (8), 2476-2481, 2004 | 999 | 2004 |
| Suppression of angiogenesis and tumor growth by the inhibitor K1–5 generated by plasmin-mediated proteolysis R Cao, HL Wu, N Veitonmäki, P Linden, J Farnebo, GY Shi, Y Cao Proceedings of the National Academy of Sciences 96 (10), 5728-5733, 1999 | 275 | 1999 |
| Bispecific antibodies in cancer immunotherapy E Dahlén, N Veitonmäki, P Norlén Therapeutic advances in vaccines and immunotherapy 6 (1), 3-17, 2018 | 199 | 2018 |
| Angiomotin regulates endothelial cell-cell junctions and cell motility A Bratt, O Birot, I Sinha, N Veitonmäki, K Aase, M Ernkvist, L Holmgren Journal of Biological Chemistry 280 (41), 34859-34869, 2005 | 188 | 2005 |
| p130‐Angiomotin associates to actin and controls endothelial cell shape M Ernkvist, K Aase, C Ukomadu, J Wohlschlegel, R Blackman, ... The FEBS journal 273 (9), 2000-2011, 2006 | 130 | 2006 |
| Endothelial cell surface ATP synthase-triggered caspase-apoptotic pathway is essential for k1-5-induced antiangiogenesis N Veitonmäki, R Cao, LH Wu, TL Moser, B Li, SV Pizzo, B Zhivotovsky, ... Cancer research 64 (10), 3679-3686, 2004 | 120 | 2004 |
| Kringle structures and antiangiogenesis Y Cao, R Cao, N Veitonmaki Current Medicinal Chemistry-Anti-Cancer Agents 2 (6), 667-681, 2002 | 110 | 2002 |
| The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell–dependent tumor immunity SM Mangsbo, S Broos, E Fletcher, N Veitonmäki, C Furebring, E Dahlén, ... Clinical Cancer Research 21 (5), 1115-1126, 2015 | 102 | 2015 |
| A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth L Holmgren, E Ambrosino, O Birot, C Tullus, N Veitonmäki, T Levchenko, ... Proceedings of the National Academy of Sciences 103 (24), 9208-9213, 2006 | 99 | 2006 |
| The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation AM Kvarnhammar, N Veitonmäki, K Hägerbrand, A Dahlman, KE Smith, ... Journal for immunotherapy of cancer 7, 1-14, 2019 | 94 | 2019 |
| Differential roles of p80-and p130-angiomotin in the switch between migration and stabilization of endothelial cells M Ernkvist, O Birot, I Sinha, N Veitonmaki, S Nyström, K Aase, L Holmgren Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1783 (3), 429-437, 2008 | 94 | 2008 |
| Immortalization of bovine capillary endothelial cells by hTERT alone involves inactivation of endogenous p16INK4A/pRb N Veitonmäki, J Fuxe, M Hultdin, G Roos, RF Pettersson, Y Cao The FASEB Journal 17 (6), 764-766, 2003 | 76 | 2003 |
| First‐in‐human study with intratumoral administration of a CD40 agonistic antibody, ADC‐1013, in advanced solid malignancies SMM Irenaeus, D Nielsen, P Ellmark, J Yachnin, A Deronic, A Nilsson, ... International journal of cancer 145 (5), 1189-1199, 2019 | 73 | 2019 |
| Elevated levels of urine angiostatin and plasminogen/plasmin in cancer patients. Y Cao, N Veitonmaki, K Keough, H Cheng, LS Lee, D Zurakowski International journal of molecular medicine 5 (5), 547-598, 2000 | 73 | 2000 |
| A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo N Veitonmäki, M Hansson, F Zhan, A Sundberg, T Löfstedt, A Ljungars, ... Cancer cell 23 (4), 502-515, 2013 | 72 | 2013 |
| Therapeutic antibodies targeting angiomotin inhibit angiogenesis in vivo T Levchenko, N Veitonmaki, A Lundkvist, H Gerhardt, Y Ming, K Berggren, ... The FASEB Journal 22 (3), 880-889, 2008 | 48 | 2008 |
| Highly potent anti-SARS-CoV-2 multi-DARPin therapeutic candidates M Walser, S Rothenberger, DL Hurdiss, A Schlegel, V Calabro, ... Biorxiv, 2020.08. 25.256339, 2020 | 37 | 2020 |
| Gene transfer of kringle 1–5 suppresses tumor development and improves prognosis of mice with hepatocellular carcinoma T Torimura, T Ueno, M Kin, E Taniguchi, T Nakamura, K Inoue, R Sakata, ... Gastroenterology 130 (4), 1301-1310, 2006 | 19 | 2006 |
| A multispecific anti-CD40 DARPin construct induces tumor-selective CD40 activation and tumor regression N Rigamonti, N Veitonmäki, C Domke, S Barsin, S Jetzer, O Abdelmotaleb, ... Cancer Immunology Research 10 (5), 626-640, 2022 | 9 | 2022 |
| Anti-CD40 antibodies P Ellmark, KE Smith, N Veitonmaki US Patent 10,577,425, 2020 | 6 | 2020 |
